WGS Quote, Financials, Valuation and Earnings

Delcath Systems has a net margin of -7.5% compared to GeneDx Holdings's net margin of 5.4%. GeneDx Holdings's return on equity of -17.4% beat Delcath Systems's return on equity of -40.28%.

GeneDx Holdings has a consensus price target of $95.04, signalling upside risk potential of 42.1%. On the other hand Delcath Systems has an analysts' consensus of $24.08 which suggests that it could grow by 56.05%. Given that Delcath Systems has higher upside potential than GeneDx Holdings, analysts believe Delcath Systems is more attractive than GeneDx Holdings.

GeneDx Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Delcath Systems has a beta of 0.948, suggesting its less volatile than the S&P 500 by 5.238%.

GeneDx Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Delcath Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GeneDx Holdings pays -- of its earnings as a dividend. Delcath Systems pays out -- of its earnings as a dividend.

GeneDx Holdings quarterly revenues are $87.1M, which are larger than Delcath Systems quarterly revenues of $19.8M. GeneDx Holdings's net income of -$6.5M is lower than Delcath Systems's net income of $1.1M. Notably, GeneDx Holdings's price-to-earnings ratio is -- while Delcath Systems's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GeneDx Holdings is 5.55x versus 9.47x for Delcath Systems. Usually stocks with elevated PS ratios are considered overvalued.

Exact Sciences has a net margin of -7.5% compared to GeneDx Holdings's net margin of -14.32%. GeneDx Holdings's return on equity of -17.4% beat Exact Sciences's return on equity of -35.57%.

GeneDx Holdings has a consensus price target of $95.04, signalling upside risk potential of 42.1%. On the other hand Exact Sciences has an analysts' consensus of $68.86 which suggests that it could grow by 29.19%. Given that GeneDx Holdings has higher upside potential than Exact Sciences, analysts believe GeneDx Holdings is more attractive than Exact Sciences.

GeneDx Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Exact Sciences has a beta of 0.977, suggesting its less volatile than the S&P 500 by 2.282%.

GeneDx Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Exact Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GeneDx Holdings pays -- of its earnings as a dividend. Exact Sciences pays out -- of its earnings as a dividend.

GeneDx Holdings quarterly revenues are $87.1M, which are smaller than Exact Sciences quarterly revenues of $706.8M. GeneDx Holdings's net income of -$6.5M is higher than Exact Sciences's net income of -$101.2M. Notably, GeneDx Holdings's price-to-earnings ratio is -- while Exact Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GeneDx Holdings is 5.55x versus 3.49x for Exact Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Illumina has a net margin of -7.5% compared to GeneDx Holdings's net margin of 12.58%. GeneDx Holdings's return on equity of -17.4% beat Illumina's return on equity of -34.38%.

GeneDx Holdings has a consensus price target of $95.04, signalling upside risk potential of 42.1%. On the other hand Illumina has an analysts' consensus of $108.48 which suggests that it could grow by 20.2%. Given that GeneDx Holdings has higher upside potential than Illumina, analysts believe GeneDx Holdings is more attractive than Illumina.

GeneDx Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Illumina has a beta of 1.324, suggesting its more volatile than the S&P 500 by 32.43%.

GeneDx Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Illumina offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GeneDx Holdings pays -- of its earnings as a dividend. Illumina pays out -- of its earnings as a dividend.

GeneDx Holdings quarterly revenues are $87.1M, which are smaller than Illumina quarterly revenues of $1B. GeneDx Holdings's net income of -$6.5M is lower than Illumina's net income of $131M. Notably, GeneDx Holdings's price-to-earnings ratio is -- while Illumina's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GeneDx Holdings is 5.55x versus 3.31x for Illumina. Usually stocks with elevated PS ratios are considered overvalued.

Star Equity Holdings has a net margin of -7.5% compared to GeneDx Holdings's net margin of -9.1%. GeneDx Holdings's return on equity of -17.4% beat Star Equity Holdings's return on equity of -15.99%.

GeneDx Holdings has a consensus price target of $95.04, signalling upside risk potential of 42.1%. On the other hand Star Equity Holdings has an analysts' consensus of $8.50 which suggests that it could grow by 329.29%. Given that Star Equity Holdings has higher upside potential than GeneDx Holdings, analysts believe Star Equity Holdings is more attractive than GeneDx Holdings.

GeneDx Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Star Equity Holdings has a beta of 1.002, suggesting its more volatile than the S&P 500 by 0.203%.

GeneDx Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Star Equity Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GeneDx Holdings pays -- of its earnings as a dividend. Star Equity Holdings pays out -19.54% of its earnings as a dividend.

GeneDx Holdings quarterly revenues are $87.1M, which are larger than Star Equity Holdings quarterly revenues of $12.9M. GeneDx Holdings's net income of -$6.5M is lower than Star Equity Holdings's net income of -$1.2M. Notably, GeneDx Holdings's price-to-earnings ratio is -- while Star Equity Holdings's PE ratio is 0.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GeneDx Holdings is 5.55x versus 0.11x for Star Equity Holdings. Usually stocks with elevated PS ratios are considered overvalued.